Press release
Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market to Surpass USD 2.6 Billion by 2034
Chemotherapy-Induced Peripheral Neuropathy
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/47961
Key Takeaways
• Market Size (2024): USD 1.2 Billion
• Forecast (2034): USD 2.6 Billion
• CAGR (2025-2034): 8.0%
• Key Segments: Drug Class, Mechanism of Action, Distribution Channel, and Region
• Leading Companies: Pfizer Inc., Novartis AG, Lilly Pharmaceuticals, Helixmith Co. Ltd., Sorrento Therapeutics, Regenacy Pharmaceuticals, Astellas Pharma Inc., and NeuroBo Pharmaceuticals
Market Story
Chemotherapy-induced peripheral neuropathy affects up to 68% of patients receiving cytotoxic therapy, causing pain, numbness, and functional impairment that often limit dosing or force early treatment cessation. The medical community is shifting from symptomatic relief to mechanism-based neuroprotection and nerve-repair strategies.
Recent breakthroughs include VEGF-based nerve-growth modulation, gene therapy candidates, and non-opioid analgesics targeting oxidative stress and mitochondrial dysfunction. Biopharma firms are collaborating with oncology centers to integrate predictive biomarkers and digital sensory testing tools for early detection of CIPN risk. Meanwhile, AI-supported rehabilitation and wearable neuromodulation devices are enhancing recovery outcomes.
Market Segmentation
By Drug Class: Anticonvulsants, Antidepressants, Opioids, Topical Agents, Others
By Mechanism of Action: Neuroprotective Agents, Anti-Inflammatory Compounds, Ion-Channel Modulators, Regenerative Therapies
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Region: North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Explore Full Report here: https://exactitudeconsultancy.com/reports/47961/chemotherapy-induced-peripheral-neuropathy-market
Recent Developments
• Pfizer Inc. advanced its pipeline compound PF-06649751 for neuropathic pain into Phase II clinical trials.
• Helixmith Co. Ltd. reported positive Phase II data for its gene therapy Engensis (VM202) in diabetic and chemotherapy-related neuropathy.
• Regenacy Pharmaceuticals initiated global studies of Ricolinostat (HDAC6 inhibitor) for sensory-nerve repair.
• Sorrento Therapeutics launched pre-clinical programs on non-opioid analgesic nanoparticles targeting CIPN.
• Novartis AG partnered with academic centers to validate digital biomarker platforms for pain-response monitoring.
Expert Insight
"CIPN is evolving from an unavoidable side effect to a treatable, monitorable condition. The convergence of neuroregeneration, digital tracking, and personalized oncology is unlocking measurable quality-of-life gains,"
- Lead Analyst, Exactitude Consultancy.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=47961
Market Drivers
• Rising Cancer Burden: Higher chemotherapy utilization in breast, lung, and colorectal cancers.
• Non-Opioid Innovation: Focus on safer pain-relief modalities reducing dependency risks.
• Regulatory Support: Fast-track approvals for orphan neuropathy drugs and FDA Breakthrough designations.
• Technological Integration: AI-based nerve-damage assessment and neurofeedback rehabilitation tools.
Forecast & Regional Insights
North America accounts for over 42% of the market in 2024, driven by established oncology infrastructure and clinical trial activity. Europe follows with strong adoption of digital neurology tools and patient support programs. Asia Pacific is expected to record the fastest CAGR of 9.3%, supported by expanding cancer care centers and increasing awareness across Japan, China, and India.
Conclusion
The Chemotherapy-Induced Peripheral Neuropathy market is undergoing a scientific renaissance, shifting focus from palliative care to nerve protection and regeneration. Strategic alliances between oncology and neuroscience research are expected to accelerate the introduction of disease-modifying therapies and personalized rehabilitation solutions over the next decade.
This report is also available in the following languages : Japanese (化学療法誘発性末梢神経障害), Korean (화학요법으로 유발된 말초신경병증), Chinese (化疗诱发的周围神经病变), French (Neuropathie périphérique induite par la chimiothérapie), German (Chemotherapie-induzierte periphere Neuropathie), and Italian (Neuropatia periferica indotta da chemioterapia), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/47961/chemotherapy-induced-peripheral-neuropathy-market#request-a-sample
Related Reports
United States Chemotherapy Induced Peripheral Neuropathy Treatment Market
https://exactitudeconsultancy.com/reports/48143/united-states-chemotherapy-induced-peripheral-neuropathy-treatment-market
Peripheral Neuropathy Market
https://exactitudeconsultancy.com/reports/49859/peripheral-neuropathy-market
Diabetic Peripheral Neuropathy Market
https://exactitudeconsultancy.com/reports/71902/diabetic-peripheral-neuropathy-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market to Surpass USD 2.6 Billion by 2034 here
News-ID: 4259522 • Views: …
More Releases from Exactitude Consultancy
Medical Robotics Market to Reach USD 46.7 Billion by 2034 Driven by AI Integrati …
Sub-headline: Rapid adoption of robotic-assisted surgeries and automation in rehabilitation and hospital logistics are reshaping global healthcare efficiency.
Pune, India, November 7, 2025 - The Global Medical Robotics Market is projected to grow from USD 17.5 billion in 2024 to approximately USD 46.7 billion by 2034, registering a CAGR of 10.2% during the forecast period (2025-2034), according to Exactitude Consultancy. This remarkable growth is attributed to continuous technological advancements, increasing demand…
X-Ray Flat Panel Detector Market to Reach USD 5.1 Billion by 2034
Pune, India, November 7, 2025 - The Global X-Ray Flat Panel Detector (FPD) Market is projected to grow from USD 2.7 billion in 2024 to USD 5.1 billion by 2034, expanding at a CAGR of 6.5% during 2025-2034, according to Exactitude Consultancy. Rising healthcare digitization, AI integration in radiology workflows, and growing use of portable imaging systems are fueling steady growth worldwide.
Download Full PDF Sample Copy of Market Report @…
Branded Generics Market to Reach USD 487.3 Billion by 2034
Pune, India, November 7, 2025 - The Global Branded Generics Market is projected to grow from USD 270.5 billion in 2024 to USD 487.3 billion by 2034, registering a steady CAGR of 6.2% during the forecast period (2025-2034), according to Exactitude Consultancy. Growth is driven by pharmaceutical companies leveraging patent cliffs, expanding their branded portfolios, and increasing the penetration of cost-effective therapies across emerging markets.
Download Full PDF Sample Copy of…
Proton Therapy Systems Market to Surpass USD 3.25 Billion by 2034
Sub-headline: Growing preference for precision radiation therapy and rapid technological advancements in compact proton systems are accelerating market expansion.
Pune, India, November 7, 2025 - The Global Proton Therapy Systems Market is projected to grow from USD 1.56 billion in 2024 to approximately USD 3.25 billion by 2034, registering a CAGR of 7.6% during the forecast period (2025-2034), according to Exactitude Consultancy. This strong growth is driven by increasing global cancer…
More Releases for Peripheral
Peripheral Vascular Devices Market - Advancing vascular health: Cutting-edge dev …
Newark, New Castle, USA: The "Peripheral Vascular Devices Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Peripheral Vascular Devices Market: https://www.growthplusreports.com/report/peripheral-vascular-devices-market/7820
This latest report researches the industry structure,…
Peripheral Stent Market - Pioneering Solutions for Peripheral Artery Disease: Re …
Newark, New Castle, USA - Growth Plus Reports has published a new report on Peripheral Stent Market, which includes a detailed analysis based on competitors and important market segments (2023-2031). The Global Peripheral Stent provides a thorough analysis of many segments such as opportunities, market size, developments, innovation, sales, and overall growth of leading players. The research is based on primary and secondary statistical data, and it includes both intuitive…
Peripheral Vascular Devices Market - Empowering Mobility, Preserving Health: Ele …
Newark, New Castle, USA - new report, titled Peripheral Vascular Devices Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Peripheral Vascular Devices market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Peripheral Vascular Devices market. The report offers an overview of…
Peripheral Vascular Devices Market Report 2018: Segmentation by Types (Periphera …
Global Peripheral Vascular Devices market research report provides company profile for Abbott Vascular, Bayer Healthcare, Volcano Corporation, Teleflex Medical and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc. The report also provides detailed segmentation…
Peripheral Vascular Device Market Size, Peripheral Vascular Device Market Share, …
Global Peripheral Vascular Device Market Size is observed to gain traction owing to the factors such as increasing research and development for developing several new product, and rising funding by the private organizations.
Request for Sample of This Research Report @ https://bit.ly/2xjOKpC
Top Key Player:-
Abbott Laboratories
Braun Melsungen AG
Boston Scientific Corporation
R. Brad, Inc.
Cardinal Health, Inc.
Medtronic plc.
Cook Medical, Inc.
Teruma Corporation
Jude Medical, Inc.
The Spectranetics Corporation
Volcano Corporation
Peripheral vascular disorder (PVD) is a blood circulation disorder…
Peripheral Artery Disease Market By Type (Peripheral Angioplasty Balloons, Perip …
Peripheral artery disease is characterized by plaque built up in the arteries carrying blood from heart to legs, arms, and other limbs. Peripheral artery disease in turn also increases the risk of other cardiovascular disorders such as heart attack, coronary heart disease, stroke, and ischemic attack.
Request Sample At: https://www.bigmarketresearch.com/request-sample/1633533
The global peripheral artery disease market generated $3,136 million in 2016, and is projected to reach $4,980 million by 2023, registering a…
